Screen-Free bedtimes may amplify bedwetting medication
NCT ID NCT07776977
First seen Aug 20, 2026 · Last updated Aug 25, 2026 · Updated 3 times
Summary
This trial tests whether limiting digital-device use for at least an hour before bed can improve the response to desmopressin, a medication that reduces nighttime urine production, in children aged 6 to 14 with primary monosymptomatic nocturnal enuresis (bedwetting). Participants will take desmopressin nightly for 8 weeks and be randomly assigned to either restrict bedtime screen time or maintain their usual habits. The study will measure how many children achieve dry nights and whether the benefit lasts after treatment stops.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Desmopressin (a medication to reduce nighttime urine production) combined with a behavioral intervention: restricting digital-device use for at least 60 minutes before bedtime.
- What this could lead to
- If limiting bedtime screen time improves the effectiveness of desmopressin, it could offer a simple, drug-free addition to help children with bedwetting achieve dry nights.
- What could go wrong
- This is a relatively small trial, and the benefit of screen restriction is uncertain. The results may not apply to all children, and desmopressin can have side effects like headache or low sodium levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 140 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2026
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 14 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 6-14 years. * Diagnosis of PMNE (≥2 wet nights/week for ≥6 months, no daytime symptoms, no prior sustained dryness \>6 months). * Willingness to take oral desmopressin nightly for 8 weeks. * Parent/guardian able to monitor and report screen time and wet nights. * Written informed consent from parent/guardian and assent from child (if age-appropriate). Exclusion Criteria: * Secondary enuresis or non-monosymptomatic enuresis (daytime incontinence, urgency, frequency). * Known organic causes (e.g., diabetes mellitus, urinary tract anomalies, neurological disorders). * Current use of other enuresis treatments (alarms, anticholinergics, imipramine) within 4 weeks prior to enrollment. * Severe sleep disorders (e.g., obstructive sleep apnea) or psychiatric conditions affecting compliance. * Inability to comply with study procedures or follow-up.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary monosymptomatic nocturnal enuresis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Urology, Al-Hussein and Sayed Galal University Hospitals, Al-Azhar University
RECRUITINGCairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.